Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
Vertex(VRTX) ZACKS·2024-08-02 23:05
Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of 11.50. In the year-ago quarter, Vertex recorded adjusted earnings of 4.9 billion acquisition of Alpine Immune Sciences, which was closed in May.The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fig ...